Metropolitan Life Insurance Company (MetLife)’s Singular Genomics Systems, Inc. Common Stock OMIC Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio OMIC Stock Details OMIC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-135	Closed	-$8.14K	–	2493
2022 Q4	$8.14K	Buy	+135	New	+$9.05K	﹤0.01%	2323
2022 Q3	–	Sell	-18	Closed	-$2.07K	–	2372
2022 Q2	$2.07K	Sell	18 -102	-85%	-$12K	﹤0.01%	2357
2022 Q1	$22.6K	Buy	+120	New	+$27.8K	﹤0.01%	2030

Other funds holding OMIC

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

AVM

Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Metropolitan Life Insurance Company (MetLife)'s OMIC Position: Q1 2023 in Review

Metropolitan Life Insurance Company (MetLife) sold out of Singular Genomics Systems, Inc. Common Stock (OMIC) in Q1 2023, closing a stake of 135 shares — an estimated $8.14K sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in OMIC in Q1 2022 and held it in 3 quarters. The position peaked at $22.6K in Q1 2022. 66 funds tracked by Wall St. Rank hold OMIC as of Q1 2023.

Metropolitan Life Insurance Company (MetLife) reported no remaining Singular Genomics Systems, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
Metropolitan Life Insurance Company (MetLife) sold 135 Singular Genomics Systems, Inc. Common Stock shares in Q1 2023, an estimated $8.14K.
Metropolitan Life Insurance Company (MetLife) first reported a position in Singular Genomics Systems, Inc. Common Stock in Q1 2022 and held it in 3 quarters.
Metropolitan Life Insurance Company (MetLife)'s Singular Genomics Systems, Inc. Common Stock position peaked at $22.6K in Q1 2022.
66 funds tracked by Wall St. Rank held Singular Genomics Systems, Inc. Common Stock as of Q1 2023.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q1 2023, filed 15 May 2023.